Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued …

The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which
displays notable immune escape potential through mutations at key antigenic sites on the …

Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are
efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably …

Omicron variant strains encode large numbers of changes in the spike protein compared to
historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several …

Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ
transplant recipients (SOTR) are not well described in the literature. The objective of this …

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

Summary In November 2021, Omicron BA. 1, containing a raft of new spike mutations,
emerged and quickly spread globally. Intense selection pressure to escape the antibody …

The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

6 Sheward DJ, Kim C, Fischbach J, et al. Evasion of neutralising antibodies by omicron
sublineage BA. 2.75. Lancet Infect Dis 2022; published online Sept 1. https://doi …

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years …